| Literature DB >> 33809840 |
Anna-Sophia Wahl1, Gloria Benson1, Lucrezia Hausner1, Sandra Schmitt1, Annika Knoll1, Adriana Ferretti-Bondy1, Dimitri Hefter1, Lutz Froelich1.
Abstract
BACKGROUND: The COVID-19 pandemic and governmental lockdown measures disproportionally impact older adults. This study presents the results from a psychiatric helpline for older adults in Mannheim, Germany, during the lockdown, set up to provide information and psychosocial support. We aim to elucidate the needs of older adults, their reported changes, and the psychological impact during the initial stages of the health crisis.Entities:
Keywords: COVID-19; anxiety; depression; elderly; hotline; psychological impact; quarantine
Year: 2021 PMID: 33809840 PMCID: PMC8006039 DOI: 10.3390/geriatrics6010030
Source DB: PubMed Journal: Geriatrics (Basel) ISSN: 2308-3417
Figure 1(A) Histogram showing the frequency of calls/week received at the geriatric helpline. (B) Graph depicting the reasons for calling the geriatric helpline. (C) Demographic characteristics of callers. N responded = the number of callers who were willing to answer the question. N represents the number of callers who affirmed the specific information and features asked. The percentage was calculated as (N/N responded) × 100.
Demographic and clinical characteristics assessing medical history and previous psychiatric and psychotherapy treatment and experience. N responded = the number of callers who were willing to answer the question. N represents the number of callers who affirmed the specific information and features asked. The percentage was calculated as (N/N responded) × 100.
| N or M (SD) | (%) | |
|---|---|---|
|
| 46 | 88.5 |
| Cardiovascular | 24 | 46.2 |
| Chronic lung disease | 14 | 26.9 |
| Diabetes | 8 | 15.4 |
| Current or previously diagnosed cancer | 12 | 23.1 |
| Neurological diseases | 10 | 19.2 |
|
| ||
| Less than one | 13 | 27.1 |
| More than one | 35 | 72.9 |
|
| ||
| Psychiatric medication | 15 | 31.3 |
| Antihypertensive or cardiac medication | 18 | 37.5 |
| Antidiabetic medication | 6 | 12.5 |
| COPD or asthma medication | 10 | 20.8 |
|
| 20 | 38.5 |
| Anxiety | 4 | 7.7 |
| Depression | 17 | 32.7 |
| Psychosis | 1 | 1.9 |
| Addiction | 4 | 7.7 |
|
| ||
| Currently seeing a psychiatrist | 11 | 21.2 |
| Previously seen a psychiatrist | 5 | 9.6 |
| Never in psychiatric treatment | 33 | 67.3 |
|
| ||
| No previous therapy | 35 | 67.3 |
| Consultation or less than 6 months | 7 | 13.5 |
| Psychotherapy more than 6 months | 4 | 7.7 |
| Continuous psychotherapy over years | 6 | 11.5 |
Figure 2(A) Table depicting changes in daily living and in the financial situation due to the COVID-19 pandemic and lockdown measures. N responded = the number of callers who were willing to answer the question. N represents the number of callers who affirmed the specific information and features asked. (B) While the social interaction with one’s partner remained stable, callers reported fewer social interactions with all other relatives (including children, grandchildren, parents, and siblings) during the crisis. (C) The number of social interactions also decreased during the COVID-19 pandemic; while most participants had >10 social interactions in person per week before COVID-19, most callers reported a decrease in all personal social interactions to 2–5/week during the lockdown measures.
Figure 3(A) Reported new psychiatric symptoms and loss of coping strategies during the COVID-19 pandemic. N responded = the number of callers who were willing to answer the question. N represents the number of callers who affirmed the specific information and features asked. The percentage was calculated as (N/N responded) * 100. (B) Mean scores and frequency of the Hamilton Depression Rating Scale (HAM-D) and (C) the Hamilton Anxiety Rating Scale (HAM-A) assessments. (D) Pie charts revealing the level of depressive or anxiety symptoms: A third (33.3%) showed no depressive symptoms (I) versus 42.2% with mild levels (II) and 24.4% with moderate levels (III). For the HAM-A, 60% of callers showed mild levels of anxiety (level I) versus 28.6% with moderate (II) and 11.4% with moderate to severe (III) levels of anxiety. We found neither severe (level IV) depressive nor anxious symptoms among the participants.
Associations between sociodemographic variables and mental health status. Differences in mean levels between categories were assessed via t-test. Individuals living alone reported higher anxiety symptoms than those living with others. Individuals with a prediagnosed psychiatric disorder reported more anxiety and depressive symptoms than callers without. Callers currently taking psychiatric medications reported significantly more depressive and anxiety symptoms. There were no differences among those at higher risk for COVID-19 or those engaging in frequent social interactions. Age was negatively correlated with higher levels of depressive and anxiety symptoms. Significant p values (p < 0.05) are shown in bold.
|
| ||||||
|---|---|---|---|---|---|---|
|
|
| Mean | SD |
| Cohen’s d |
|
|
| ||||||
| No | 22 | 8.41 | 5.578 | 1.371 | 0.41 | 0.178 |
| Yes | 22 | 6.05 | 5.851 | |||
|
| ||||||
| No | 26 | 5.00 | 4.964 | −3.441 |
|
|
| Yes | 18 | 10.44 | 5.437 | |||
|
| ||||||
| No | 26 | 5.58 | 4.933 | −3.33 |
|
|
| Yes | 15 | 11.13 | 5.475 | |||
|
| ||||||
| No | 32 | 7.09 | 6.061 | −0.584 | 0.20 | 0.563 |
| Yes | 11 | 8.27 | 4.798 | |||
|
| ||||||
| No | 24 | 8.00 | 6.386 | 0.972 | 0.21 | 0.337 |
| Yes | 20 | 6.3 | 4.943 | |||
|
|
| |||||
| Age | −0.293 | 0.054 | ||||
|
| ||||||
|
|
|
|
|
|
| |
|
| ||||||
| No | 17 | 17.53 | 8.84 | 2.569 |
|
|
| Yes | 18 | 10.72 | 6.755 | |||
|
| ||||||
| No | 20 | 9.9 | 7.174 | −4.006 |
|
|
| Yes | 15 | 19.53 | 6.854 | |||
|
| ||||||
| No | 21 | 11.43 | 7.972 | −2.97 |
|
|
| Yes | 12 | 19.67 | 7.075 | |||
|
| ||||||
| No | 27 | 13.07 | 8.185 | −1.236 | 0.50 | 0.225 |
| Yes | 8 | 17.25 | 9.114 | |||
|
| ||||||
| No | 19 | 13.63 | 9.552 | −0.299 | 0.10 | 0.762 |
| Yes | 16 | 14.5 | 7.22 | |||
|
|
| |||||
| Age | −0.34 |
| ||||